当前位置： SCI文献检索 > INVESTIGATIONAL NEW DRUGS期刊下所有文献 > Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.

Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.

Abstract：

:Breast cancer is commonly treated with anti-estrogens or aromatase inhibitors, but resistant disease eventually develops and new therapies for such resistance are of great interest. We have previously isolated several tamoxifen-resistant variant sub-lines of the MCF-7 breast cancer cell line and provided evidence that they arose from expansion of pre-existing minor populations. We have searched for therapeutic agents that exhibit selective growth inhibition of the resistant lines and here investigate 2,6-bis(pyridin-3-ylmethylene)-cyclohexanone (RL90) and 2,6-bis(pyridin-4-ylmethylene)-cyclohexanone (RL91). We found that two of the tamoxifen-resistant sub-lines (TamR3 and TamC3) unexpectedly showed increased sensitivity to RL90 and RL91. We utilized growth inhibition assays, flow cytometry and immunoblotting to establish a mechanistic basis for their action. Treated sensitive cells showed S-phase selective DNA damage, as detected by histone H2AX phosphorylation. Cellular responses were similar to those induced by the topoisomerase I poison camptothecin. Although IC(50) values of camptothecin, RL90, RL91 were correlated, studies with purified mammalian topoisomerase I suggested that RL90 and RL91 differed from camptothecin by acting as catalytic topoisomerase I inhibitors. These drugs provide a platform for the further development of DNA damaging drugs that have selective effects on tamoxifen resistant breast cancer cells. The results also raise the question of whether clinical topoisomerase I poisons such as irinotecan and topotecan might be active in the treatment of some types of tamoxifen-resistant cancer.

journal_name

Invest New Drugs

journal_title

Investigational new drugs

authors

Leung E,Rewcastle GW,Joseph WR,Rosengren RJ,Larsen L,Baguley BC

doi

10.1007/s10637-011-9768-4

subject

Has Abstract

pub_date

2012-12-01 00:00:00

pages

2103-12

issue

6

eissn

0167-6997

issn

1573-0646

journal_volume

30

pub_type

杂志文章

相关文献

INVESTIGATIONAL NEW DRUGS文献大全
  • A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.

    abstract：PURPOSE:BMS-275183 is an oral C-4 methyl carbonate analogue of paclitaxel that has the same mechanism of action, stabilization of tubulin polymerization. The present study was designed to: (i) assess the safety and tolerability of BMS-275183, and (ii) determine a suitable Phase II dose of BMS-275183 when given on a con...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-010-9498-z

    authors： Heath EI,Lorusso P,Ramalingam SS,Awada A,Egorin MJ,Besse-Hamer T,Cardoso F,Valdivieso M,Has T,Alland L,Zhou X,Belani CP

    更新日期：2011-12-01 00:00:00

  • Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.

    abstract：PURPOSE:To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC). PATIENTS AND METHODS:Patients with Stage III unresectable or Stage IV...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10637-010-9598-9

    authors： Madajewicz S,Waterhouse DM,Ritch PS,Khan MQ,Higby DJ,Leichman CG,Malik SK,Hentschel P,Gill JF,Zhao L,Nicol SJ

    更新日期：2012-04-01 00:00:00

  • N-benzoxazol-2-yl-N'-1-(isoquinolin-3-yl-ethylidene)-hydrazine, a novel compound with antitumor activity, induces radicals and dissipation of mitochondrial membrane potential.

    abstract：:The novel compound N-benzoxazol-2-yl-N'-1-(isoquinolin-3-yl-ethylidene)-hydrazine (EPH136) has been shown to exhibit antitumor activity in vitro and in vivo. A COMPARE analysis showed that the patterns of cellular effects of EPH136 are not related to any of 175 standard antitumor agents with a known mechanism of actio...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-008-9156-x

    authors： Hofmann J,Easmon J,Puerstinger G,Heinisch G,Jenny M,Shtil AA,Hermann M,Condorelli DF,Sciré S,Musumarra G

    更新日期：2009-06-01 00:00:00

  • Dual modulation of JNK and Akt signaling pathways by chaetoglobosin K in human lung carcinoma and ras-transformed epithelial cells.

    abstract：:Chaetoglobosin K (ChK) is a natural product that inhibits anchorage-dependent and anchorage-independent growth of ras-transformed cells, prevents tumor-promoter disruption of cell-cell communication, and reduces Akt activation in tumorigenic cells. This study demonstrates how ChK modulates the JNK pathway in ras-trans...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-012-9883-x

    authors： Ali A,Sidorova TS,Matesic DF

    更新日期：2013-06-01 00:00:00

  • Crizotinib-induced simultaneous multiple cardiac toxicities.

    abstract：:Crizotinib is a receptor tyrosine kinase inhibitor that has several targets, including c-ros oncogene 1 and the MET proto-oncogene. Considering its known cardiac toxicity, bradycardia is often investigated following treatment with crizotinib. Our patients had bradycardia, QT prolongation, ventricular rhythm, ventricul...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-018-0605-x

    authors： Oyakawa T,Muraoka N,Iida K,Kusuhara M,Kawamura T,Naito T,Takahashi T

    更新日期：2018-10-01 00:00:00

  • Sequential studies on the role of mitoxantrone in the treatment of acute leukemia.

    abstract：:Mitoxantrone (Novantrone; 1, 4-dihydroxy-5, 8-bis [[2-[(2-hydroxyethyl) amino]ethyl]amino-] 9, 10 anthracenedione dihydrochloride (NSC 301739] is a synthetic anthracenedione with intercalating properties. Activity has been shown in preclinical studies in mice bearing intraperitoneal P388 and L1210 leukaemias, ADJ-Pc6 ...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00174172

    authors： Prentice HG,Wimperis JZ,Robbins G

    更新日期：1985-01-01 00:00:00

  • Phase I clinical study of nafazatrom.

    abstract：:Nafazatrom, a synthetic pyrazolinone derivative, has been shown to have substantial antitumor activity in vitro and antitumor and antimetastatic activity in experimental animal systems. The drug has produced no substantial toxicity in preclinical studies and during limited human trials. A phase I clinical trial with t...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00179592

    authors： Hortobagyi GN,Papadoupoulos NE,Frye D,Ajani J,Reuben JM

    更新日期：1986-01-01 00:00:00

  • Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS).

    abstract：BACKGROUND:Based on reports of the efficacy of docetaxel (T) in STS, we undertook a phase I/II trial to determine the response rate (RR), dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of addition of T to doxorubicin (A) and ifosfamide (I) in advanced STS. METHODS:Patients with advanced, recurrent, or ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-006-9035-2

    authors： Suppiah R,Wood L,Elson P,Budd GT

    更新日期：2006-11-01 00:00:00

  • Inhibitory activity of diarylamidine derivatives on murine leukemia L1210 cell growth.

    abstract：:A series of 96 diarylamidine (and diarylimidazoline) derivatives were evaluated for their inhibitory effects on the growth and DNA synthesis of murine leukemia L1210 cells. The amidino- and imidazolino-substituted aryl moieties of the compounds consisted of phenyl, indole, indene, benzofuran, benzo[b]thiophene or benz...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00172069

    authors： Balzarini J,de Clercq E,Dann O

    更新日期：1983-01-01 00:00:00

  • Tumor therapy with a urokinase plasminogen activator-activated anthrax lethal toxin alone and in combination with paclitaxel.

    abstract：:PA-U2, an engineered anthrax protective antigen that is activated by urokinase was combined with wildtype lethal factor in the treatment of Colo205 colon adenocarcinoma in vitro and B16-BL6 mouse melanoma in vitro and in vivo. This therapy was also tested in combination with the small molecule paclitaxel, based on pri...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-012-9847-1

    authors： Wein AN,Liu S,Zhang Y,McKenzie AT,Leppla SH

    更新日期：2013-02-01 00:00:00

  • Eugenol inhibits cell proliferation via NF-κB suppression in a rat model of gastric carcinogenesis induced by MNNG.

    abstract：:The modulation of intracellular nuclear factor-kappaB (NF-κB) signaling pathway involved in the deregulated expression of cell proliferation and cell cycle regulatory molecules is a pragmatic approach for chemoprevention. Eugenol (4-allyl-1-hydroxy-2-methoxybenzene), a natural phenolic constituent of oils of cloves is...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-009-9345-2

    authors： Manikandan P,Vinothini G,Vidya Priyadarsini R,Prathiba D,Nagini S

    更新日期：2011-02-01 00:00:00

  • A phase I study of sulofenur in refractory pediatric malignant solid tumors.

    abstract：:The diarylsulfonylureas have shown promise in xenograft models of childhood cancer. Sulofenur has been evaluated in phase I and II trials in adults with a variety of solid tumors, but the toxicity and maximum tolerated dose of sulofenur in children and adolescents have not been determined. In a phase I study, sulofenu...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF02614222

    authors： Pratt CB,Bowman LC,Marina N,Pappo A,Avery L,Luo X,Meyer WH

    更新日期：1995-01-01 00:00:00

  • Phase I, dose-escalating study of elisidepsin (Irvalec(®)), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors.

    abstract：OBJECTIVE:To determine the recommended dose for phase II trials of elisidepsin (PM02734, Irvalec®) in combination with erlotinib in patients with advanced malignant solid tumors. METHODS:Open-label, dose-escalating, phase I study of intravenous elisidepsin administered weekly (days 1, 8 and 15) over 3 h as a flat dose...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-015-0305-8

    authors： Goel S,Viteri S,Morán T,Coronado C,Dios JL,Miguel-Lillo B,Fernández-García EM,Rosell R

    更新日期：2016-02-01 00:00:00

  • T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.

    abstract：:T cells are important effectors in anti-tumor immunity, and aberrant expression of B7 family members may contribute to tumor evasion. In this study, we analyzed expression of costimulatory molecules on human hematologic tumor cells and explored whether B7-H3, a member of the B7 superfamily, is an effective target for ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-019-00819-y

    authors： Sun X,Yu Y,Ma L,Xue X,Gao Z,Ma J,Zhang M

    更新日期：2020-06-01 00:00:00

  • Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.

    abstract：BACKGROUND:This Phase-I-study aimed to determine the recommended Phase-II-dosing-schedule of LY2334737, an oral gemcitabine prodrug, in patients with advanced/metastatic solid tumors. Pharmacokinetics, cytokeratin-18 (CK18) levels, genetic polymorphisms, and antitumor activity were additionally evaluated. METHODS:Pati...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-015-0286-7

    authors： Faivre SJ,Olszanski AJ,Weigang-Köhler K,Riess H,Cohen RB,Wang X,Myrand SP,Wickremsinhe ER,Horn CL,Ouyang H,Callies S,Benhadji KA,Raymond E

    更新日期：2015-12-01 00:00:00

  • Atezolizumab plus carboplatin and etoposide in small cell lung cancer patients previously treated with platinum-based chemotherapy.

    abstract：:Although immune checkpoint inhibitors have improved the survival of small cell lung cancer (SCLC) patients, their efficacy in SCLC patients who relapsed after systemic chemotherapy is unclear. This retrospective study aimed to investigate the utility of treatment with atezolizumab plus carboplatin and etoposide in SCL...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-020-00983-6

    authors： Ishii H,Azuma K,Kawahara A,Matsuo N,Tokito T,Hoshino T

    更新日期：2020-08-11 00:00:00

  • A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer.

    abstract：BACKGROUND:We evaluated the efficacy and safety of cetuximab in combination with XELOX [XELoda® (capecitabine) and OXaliplatin] in advanced gastric cancer (AGC) patients. The objectives were to evaluate overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety of cetuximab plus XEL...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-009-9363-0

    authors： Kim C,Lee JL,Ryu MH,Chang HM,Kim TW,Lim HY,Kang HJ,Park YS,Ryoo BY,Kang YK

    更新日期：2011-04-01 00:00:00

  • INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model.

    abstract：:The (6-maleimidocaproyl)hydrazone derivative of doxorubicin (INNO-206) is an albumin-binding prodrug of doxorubicin with acid-sensitive properties that is being assessed clinically. The prodrug binds rapidly to circulating serum albumin and releases doxorubicin selectively at the tumor site. This novel mechanism may p...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-008-9208-2

    authors： Graeser R,Esser N,Unger H,Fichtner I,Zhu A,Unger C,Kratz F

    更新日期：2010-02-01 00:00:00

  • Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.

    abstract：:Background This open-label, first-in-human, phase 1 study evaluated AMG 232, an oral selective MDM2 inhibitor in patients with TP53 wild-type (P53WT), advanced solid tumors or multiple myeloma (MM). Methods In the dose escalation (n = 39), patients with P53WT refractory solid tumors enrolled to receive once-daily AMG ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-019-00840-1

    authors： Gluck WL,Gounder MM,Frank R,Eskens F,Blay JY,Cassier PA,Soria JC,Chawla S,de Weger V,Wagner AJ,Siegel D,De Vos F,Rasmussen E,Henary HA

    更新日期：2020-06-01 00:00:00

  • Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.

    abstract：:Studies with CGP 41 251 (I), an N-benzoylstaurosporine derivative and PKC-alpha inhibitor, revealed that oral administration of 400 microg/day of the compound to wild type mice on four successive days reversed multi drug resistance (Killion et al. Oncology Research 7: 453-459, 1995). In our study, the same regimen of ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1023/a:1006260217400

    authors： van Gijn R,van Tellingen O,Haverkate E,Kettenes-van den Bosch JJ,Bult A,Beijnen JH

    更新日期：1999-01-01 00:00:00

  • Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors; the need for alternative strategies in the investigation of new agents in GCT.

    abstract：:Fifteen patients with advanced, cisplatin-refractory germ cell tumors (GCT) were treated with iproplatin (CHIP). No objective responses were noted in any of the patients treated. By restricting the entry criteria to heavily pre-treated patients, the identification of new active agents in phase II trials may be hindere...

    journal_title：Investigational new drugs

    pub_type： 临床试验,杂志文章

    doi：10.1007/BF00944190

    authors： Murphy BA,Motzer RJ,Bosl GJ

    更新日期：1992-11-01 00:00:00

  • The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a']diisoquinoline derivatives in human gastric cancer cells.

    abstract：:Objective The aim of the current study was to examine the anticancer activity and the detailed mechanism of novel diisoquinoline derivatives in human gastric cancer cells (AGS). Methods The viability of AGS cells was measured by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Cell cycle analy...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-018-0584-y

    authors： Pawłowska N,Gornowicz A,Bielawska A,Surażyński A,Szymanowska A,Czarnomysy R,Bielawski K

    更新日期：2018-12-01 00:00:00

  • In vitro activity of 4'-iodo-4'-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay.

    abstract：:A short-term antimetabolic assay based upon the inhibition of incorporation of nucleic acid precursors was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound doxorubicin (DX) on human colo-rectal carcinoma specimens. IDX showed a mar...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/BF00177248

    authors： Villa R,Zaffaroni N,Giuliani F,Colella G,Sanfilippo O,Silvestrini R

    更新日期：1990-05-01 00:00:00

  • Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplifi

    abstract：:Neuroblastoma is an extracranial, solid, and heterogeneous malignancy in children. The conventional therapeutic modalities are mostly ineffective and thus new therapeutic strategies for malignant neuroblastoma are urgently warranted. We examined the synergistic efficacy of combination of sorafenib (SF) and genistein (...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-009-9324-7

    authors： Roy Choudhury S,Karmakar S,Banik NL,Ray SK

    更新日期：2010-12-01 00:00:00

  • Continuing pursuit for ideal systemic anticancer radiotherapeutics.

    abstract：:Cancer is one of the major causes of death for non-transmissible chronic diseases worldwide. Conventional treatments including surgery, chemotherapy and external beam radiotherapy are generally far from curative. Complementary therapies are attempted for achieving more successful treatment response. Systemic targeted ...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,评审

    doi：10.1007/s10637-011-9758-6

    authors： Cona MM,Wang H,Li J,Feng Y,Chen F,de Witte P,Verbruggen A,Ni Y

    更新日期：2012-10-01 00:00:00

  • First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors.

    abstract：:Background This first-in-human phase 1 study assessed the safety of TAS-114, a novel deoxyuridine triphosphatase inhibitor, combined with S-1 to determine its maximum tolerated dose (MTD) and recommended dose (RD). Methods In this dose-escalation study with a 3 + 3 design, TAS-114 and S-1 were concurrently administere...

    journal_title：Investigational new drugs

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10637-018-0697-3

    authors： Doi T,Yoh K,Shitara K,Takahashi H,Ueno M,Kobayashi S,Morimoto M,Okusaka T,Ueno H,Morizane C,Okano N,Nagashima F,Furuse J

    更新日期：2019-06-01 00:00:00

  • UCN-01 enhances the in vitro toxicity of clinical agents in human tumor cell lines.

    abstract：:UCN-01 is undergoing Phase I evaluation and is a candidate for combination strategies in the clinic. UCN-01 has been shown to have a variety of effects on cellular targets and the cell cycle. It has also been reported to sensitize cells to several clinical drugs in vitro, possibly in a manner related to p53 status. Th...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1023/a:1006313611677

    authors： Monks A,Harris ED,Vaigro-Wolff A,Hose CD,Connelly JW,Sausville EA

    更新日期：2000-05-01 00:00:00

  • Aberrant crypt foci and AgNORs as putative biomarkers to evaluate the chemopreventive efficacy of pronyl-lysine in rat colon carcinogenesis.

    abstract：:Chemoprevention opens new perspectives in the prevention of cancer and other degenerative diseases. Use of target-organ biological models at the histological and genetic levels can markedly facilitate the identification of potential chemopreventive agents. Our aim was to study the chemopreventive efficacy of pronyl-ly...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-008-9122-7

    authors： Panneer Selvam J,Aranganathan S,Nalini N

    更新日期：2008-12-01 00:00:00

  • Enhanced antitumor activity of irofulven in combination with antimitotic agents.

    abstract：:The aim of this study was to determine the antitumor activity of irofulven when administered in combination with a variety of antimitotic agents. Irofulven in combination with either paclitaxel or docetaxel demonstrated synergistic activity in both the in vitro and in vivo studies. The majority of xenograft bearing an...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1023/a:1016201807796

    authors： Kelner MJ,McMorris TC,Rojas RJ,Trani NA,Velasco TR,Estes LA,Suthipinijtham P

    更新日期：2002-08-01 00:00:00

  • Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.

    abstract：:Alectinib, the second generation anaplastic lymphoma kinase (ALK) inhibitor, has significant potency in patients with ALK rearrangement positive non-small cell lung cancer (NSCLC), and its toxicity is generally well tolerable. We report a patient who developed severe acute interstitial lung disease after alectinib tre...

    journal_title：Investigational new drugs

    pub_type： 杂志文章

    doi：10.1007/s10637-015-0284-9

    authors： Yamamoto Y,Okamoto I,Otsubo K,Iwama E,Hamada N,Harada T,Takayama K,Nakanishi Y

    更新日期：2015-10-01 00:00:00